BridgeBio Pharma, Inc. has announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C (ON) state. BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity. BBO-8520 drives substantial tumor growth inhibition in multiple preclinical models, even after emergence of resistance to sotorasib, an FDA approved (OFF) state inhibitor of KRASG 12C.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.14 USD | +1.48% |
|
+3.73% | -35.25% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.25% | 4.82B | |
+3.11% | 97.7B | |
+4.21% | 41.43B | |
-11.86% | 32.85B | |
+80.99% | 29.33B | |
-14.25% | 15.47B | |
-7.36% | 12.89B | |
-13.08% | 11.51B | |
+176.65% | 10.74B | |
-57.36% | 8.97B |
- Stock Market
- Equities
- BBIO Stock
- News BridgeBio Pharma, Inc.
- BridgeBio Pharma, Inc. Announces FDA Clearance of IND Application for BBO-8520